Aim. To conduct an associative analysis between antipsychotic-induced metabolic disorders and the polymorphic variant NQO1 rs1800566.Materials and methods. The study included 603 patients with schizophrenia, who underwent a comprehensive clinical, anthropometric and laboratory examination. Metabolic syndrome (MetS) was established based on the 2005 International Diabetes Federation criteria. Genotyping of the polymorphic variant NQO1 rs1800566 was performed in the studied sample of patients. Statistical processing of the results was performed using Statistica 12.0 software package (StatSoft, Russia).Results. Among patients receiving basic therapy with atypical antipsychotics, the T allele had an effect predisposing to the development of MetS (odds ratio: 1.63, 95% confidence interval: 1.01–2.62), while the C allele was statistically significantly more common among patients without metabolic syndrome (odds ratio: 0.61, 95% confidence interval: 0.38–0.99). In carriers of the TT genotype, serum triglyceride levels are statistically significantly higher than in carriers of the CC or CT genotypes (p = 0.049).Conclusion. The results of the study for the first time revealed associations of the polymorphic variant NQO1 rs1800566 with MetS and hypertriglyceridemia in patients with schizophrenia receiving pharmacotherapy with second-generation antipsychotics. The results of this study confirm the contribution of the genetic component to the development of metabolic disorders in patients with schizophrenia and open up prospects for further search for genetic markers for the prevention and correction of this undesirable phenomenon.